- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04358185
Itacitinib in Advanced Hepatocellular Carcinoma (JAKaL)
A Phase Ib Study of Itacitinib, a JAK1 Inhibitor, in Advanced Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
JAKaL is a single arm phase Ib study evaluating the effect of Itacitinib in 25 patients with advanced HCC.
Many patients diagnosed with HCC will have advanced disease where only palliative care is offered to them, this could account for the relatively low reported 5-year survival rate of approximately 10%. There are a number of epidemiological and pre-clinical studies that have investigated the role of chronic inflammatory conditions in the development of HCC and these provide evidence that inflammation promotes malignant transformation. The production of tumour-promoting cytokines by inflammatory cells can activate transcription factors, such as STAT3 via the JAK/STAT pathway in premalignant cells. STAT3, once activated, can cause the expression of further genes necessary for cell activation, localisation, survival and proliferation. Inhibition of JAK could therefore be a way of directly affecting malignant cell proliferation, as STAT3 in most malignancies are persistently phosphorylated and thereby stimulated to carry out its function; to sustain cell proliferation and block apoptosis.
For reference, STAT3 is a member of the STAT protein family and is switched on, via phosphorylation, by receptor-associated Janus kinases (JAK), a type of tyrosine kinase, and together they form homo-/heterodimers that translocate to the cell nucleus and act as transcription activators. STAT3 mediates the expression of a variety of genes and therefore is integral to many cellular processes, as mentioned above, such as cell growth and apoptosis, and thus they can promote oncogenesis by being over-active in the different signalling pathways it is involved in.
Itacitinib has not yet been approved by the U.S. Food and Drug Administration (FDA) for any clinical indication but has been developed as potential treatments for myelofibrosis (MF), rheumatoid arthritis (RA), psoriasis, graft-versus-host disease (GVHD), B cell malignancies and solid tumours like HCC. It is a small molecule selective inhibitor of JAK1 thereby preventing its phosphorylation of STAT proteins, particularly STAT3, resulting in a decrease in the expression of genes responsible for cell activation, localisation, survival and proliferation
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W12 0HS
- Imperial College Healthcare NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 or over
Diagnosis of hepatocellular carcinoma. If primary diagnosis of HCC: diagnosis based on the following criteria:
- cyto-histological criteria, OR
- radiological criteria: Focal lesion >1 cm with arterial hypervascularization in 2 coincident imaging techniques (CT, MRI, or US), OR
- combined criteria: one imaging technique showing a focal lesion 1-2 cm with arterial hypervascularization AND AFP levels >400 ng/mL, OR
- combined criteria: one imaging technique showing a focal lesion >2 cm with arterial hypervascularization AND AFP levels >200 ng/mL
- Child-Pugh A and B up to 7 points (in patients receiving anticoagulant therapy; Child-Pugh score up to 5 points; INR category not regarded for calculation of the Child-Pugh score)
- Progression or intolerance to first line therapy - N.B: Date of patients last dose of therapy must be more than 28 days before enrolment into this study.
- ECOG Performance status 0, 1 or 2.
Adequate organ function as defined by:
- Adequate hematologic function (ANC 1.0x109/l, platelet count 50x109/l, and hemoglobin 9g/dl).
- Serum creatinine concentration < 1.5 times the upper limit of normal (ULN) and/or creatinine clearance >60 ml/min
- Bilirubin level < 1.5 X ULN
- PT-INR/PTT<1.5 x ULN
- For women of child-bearing potential (defined as women who have not undergone surgical sterilization with a hysterectomy, and/or bilateral oophorectomy, and are not postmenopausal, defined as ≥12 months of amenorrhea) must have a negative serum pregnancy test within 14 days prior to the first study drug administration Effective contraception must be used throughout the duration of the study and up to 30 days following the last dose of the investigational medicinal product (IMP). Effective forms of contraception include complete abstinence from sexual intercourse, double barrier methods (condom with spermicide in conjunction with use of an intrauterine device or condom with spermicide in conjunction with use of a diaphragm), birth control patch or vaginal ring, oral, injectable, or implanted contraceptives and surgical sterilization (tubal ligation or vasectomy). Sperm and ova donation are prohibited during the duration of the study and 30days after the last dose. 8. Written informed consent prior to initiation of any study procedures and willing and able to comply with the study schedule
Exclusion Criteria:
Previous treatment with:
- Study medication, any other JAK1 inhibitor and/or known hypersensitivity to the study medication
- An investigational agent within 28 days prior to start of study treatment
- Serious concurrent medical or psychiatric illness, including serious active infection
- Uncontrolled ascites
- Uncontrolled hypertension
- History of organ transplant (including prior liver transplant)
- Diagnosis of HIV, congenital immune defect, any immunosuppressive therapy for autoimmune disease or inflammatory bowel disease
- Patients with active or latent tuberculosis
- Patients with active hepatitis C or active hepatitis B that requires treatment
- Patients who have received a live vaccine 30 days or fewer prior to enrolment as well as patients who intend to receive live vaccination during study participation or for three months after last dose administration
8. Patients who have a history of unprovoked venous thromboembolism (VTE) prior to the diagnosis of malignancy 9. Pregnant or breast feeding women Other clinically significant co-morbidities that could compromise the subject's participating in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Itacitinib
Itacitinib (INCB039110) - novel and small molecule selective inhibitor of JAK1
|
Novel and small molecule selective inhibitor of JAK1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the safety and tolerability of Itacitinib in patients with HCC: adverse events
Time Frame: Throughout study completion, up to 1 year
|
Assessment of adverse events relating to experimental drug intake according to the Common Terminology Criteria for Adverse Events (CTCAE) V4.03
|
Throughout study completion, up to 1 year
|
To assess efficacy of Itacitinib by overall response rate: objective response rate (ORR)
Time Frame: Throughout study completion, up to 1 year
|
Measure objective response rate (ORR) as complete response, partial response, stable disease or progressive disease at 8 weeks post treatment according to RECIST criteria (mRECIST) V1.1
|
Throughout study completion, up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of Itacitinib by progression free survival
Time Frame: Throughout study completion, up to 1 year
|
Progression free survival (PFS), defined as time from study entry to first evidence of disease progression assessed by mRECIST v1.1 or death due to any cause
|
Throughout study completion, up to 1 year
|
Efficacy of Itacitinib by overall survival
Time Frame: Throughout study completion, up to 1 year
|
Overall survival (OS), defined as time from study entry to death due to any cause
|
Throughout study completion, up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of predefined JAK1 mutations in tumour tissue
Time Frame: Throughout study completion, up to 1 year
|
Assessment of presence of predefined JAK1 mutations in tumour tissue
|
Throughout study completion, up to 1 year
|
Translational studies
Time Frame: Throughout study completion, up to 1 year
|
Assessment of presence of predefined JAK1 mutations in ctDNA
|
Throughout study completion, up to 1 year
|
Translational studies 2
Time Frame: Throughout study completion, up to 1 year
|
Correlation of changes in proinflammatory cytokines (multiplex bead array) with treatment response (mRECIST)
|
Throughout study completion, up to 1 year
|
Correlation of JAK1 mutations with treatment
Time Frame: Throughout study completion, up to 1 year
|
Using mRECIST to find the correlation between the presence of predefined JAK1 mutations in tumour tissue with treatment outcome
|
Throughout study completion, up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 237279
- 2017-004437-81 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Hepatocellular Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterMerck Sharp & Dohme LLC; Highlight TherapeuticsTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular CarcinomaUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
AmgenCompletedAdvanced Hepatocellular Carcinoma | Inoperable Hepatocellular Carcinoma
-
The University of Hong KongUnknownAdvanced Hepatocellular Carcinoma | Metastatic Hepatocellular CarcinomaChina
-
Mayo ClinicRecruitingAdvanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8United States
-
University of WashingtonExelixisTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
Clinical Trials on Itacitinib (INCB039110)
-
Incyte CorporationCompletedRheumatoid ArthritisUnited States, Puerto Rico
-
Incyte CorporationTerminatedBronchiolitis Obliterans SyndromeUnited States, Belgium, Canada
-
Incyte CorporationCompletedPolycythemia Vera | Myelofibrosis | ThrombocythemiaSpain, United States, Germany, Austria, Belgium, Italy, Poland
-
Incyte CorporationAvailableSTAT1 Gain-of-Function Disease
-
Incyte CorporationCompletedMPN (Myeloproliferative Neoplasms)Canada, United States, Australia
-
Incyte CorporationActive, not recruitingB-cell MalignanciesUnited States
-
Incyte CorporationActive, not recruitingChronic Graft Versus Host Disease | Myelofibrosis | Postlung Transplant (Bronchiolitis Obliterans)United States, Spain, Italy, Germany, Belgium, Austria, Israel, Canada, Greece
-
M.D. Anderson Cancer CenterRecruitingBronchiolitis ObliteransUnited States
-
Incyte CorporationCompletedPlaque PsoriasisUnited States, Canada
-
Incyte CorporationTerminatedSolid TumorsUnited States